Literature DB >> 25380806

Assessing steatotic liver function after ischemia-reperfusion injury by in vivo multiphoton imaging of fluorescein disposition.

Camilla A Thorling1, Lu Jin1, Michael Weiss1, Darrell Crawford1, Xin Liu1, Frank J Burczynski1, David Liu1, Haolu Wang1, Michael S Roberts2.   

Abstract

Ischemia-reperfusion injury, a common complication during liver surgery where steatotic livers are more prone to the injury, may become more prevalent in the growing obese population. This study characterizes liver morphology toward understanding changes in subcellular function in steatotic livers exposed to ischemia-reperfusion injury through quantitative description of fluorescein distribution obtained by minimally invasive in vivo multiphoton microscopy using a physiologic pharmacokinetic model. Rats were fed a high-fat diet for 7 days to induce liver steatosis. Partial ischemia was induced after reperfusion for 4 hours, when fluorescein (10 mg/kg) was injected intravenously. Liver images, bile, and blood were collected up to 180 minutes after injection. Ischemia-reperfusion injury was associated with an increase in alanine transaminase levels and apoptosis. In addition, steatosis featured lipid droplets and an increase in fluorescein-associated fluorescence observed in hepatocytes via multiphoton imaging. Analysis of the hepatic concentration-time profiles has suggested that the steatosis-induced increase in fluorescein-associated fluorescence mainly arises by inducing hepatic fluorescein metabolism. The combination of ischemia-reperfusion with steatosis exacerbates these effects further. This was confirmed by fluorescence lifetime imaging microscopy showing a decreased average fluorescence lifetime of the liver, which is indicative of an increased production of the metabolite. Our results show the potential of noninvasive dye imaging for improving our understanding of liver disease induced by subcellular changes in vivo, providing further quantitative measures of metabolic and biliary liver function, and hence extending the qualitative liver function tests now available.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380806     DOI: 10.1124/dmd.114.060848

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Real-time histology in liver disease using multiphoton microscopy with fluorescence lifetime imaging.

Authors:  Haolu Wang; Xiaowen Liang; Yousuf H Mohammed; James A Thomas; Kim R Bridle; Camilla A Thorling; Jeffrey E Grice; Zhi Ping Xu; Xin Liu; Darrell H G Crawford; Michael S Roberts
Journal:  Biomed Opt Express       Date:  2015-02-10       Impact factor: 3.732

2.  Metabolic imaging and secondary ion mass spectrometry to define the structure and function of liver with acute and chronic pathology.

Authors:  Daria Kuznetsova; Svetlana Rodimova; Alexander Gulin; Dmitry Reunov; Nikolai Bobrov; Anastasia Polozova; Alexander Vasin; Vladislav Shcheslavskiy; Natalia Vdovina; Vladimir Zagainov; Elena Zagaynova
Journal:  J Biomed Opt       Date:  2019-12       Impact factor: 3.170

3.  Toxicological Analysis of Hepatocytes Using FLIM Technique: In Vitro versus Ex Vivo Models.

Authors:  Svetlana Rodimova; Vadim Elagin; Maria Karabut; Irina Koryakina; Alexander Timin; Vladimir Zagainov; Mikhail Zyuzin; Elena Zagaynova; Daria Kuznetsova
Journal:  Cells       Date:  2021-10-26       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.